- Glaukos Corporation (GKOS, Financial) to present at the 2025 ASCRS Annual Meeting in Los Angeles, featuring new research on glaucoma and corneal treatments.
- Key presentations include long-term data on trabecular micro-bypass stents and travoprost intracameral implants.
- Highlights include pediatric safety studies on non-invasive corneal collagen cross-linking for keratoconus.
Glaukos Corporation (GKOS), a leading ophthalmic pharmaceutical and medical technology company, will present multiple scientific abstracts at the American Society of Cataract and Refractive Surgery (ASCRS) annual meeting from April 25-28, 2025, in Los Angeles, California. The company will be showcasing its latest advancements in glaucoma and corneal treatments at booth #2227.
The company is hosting an educational symposium titled “Empowering Interventional Glaucoma Care” on April 25, 2025, featuring prominent ophthalmologists like Dr. Ike Ahmed and Dr. John Berdahl. Among the scheduled events, a presentation on the 10-year control of glaucoma using second-generation trabecular micro-bypass systems will take place.
Significant focus will be on the third-generation trabecular micro-bypass stent, revealing 12-month multicenter outcomes for patients with open-angle glaucoma. Another major highlight includes research on the travoprost intracameral implant, showing 36-month data on intraocular pressure (IOP) reduction and decreased reliance on topical IOP-lowering medications.
Additionally, new findings from Phase 3 studies on epithelium-on corneal collagen cross-linking will be presented, with emphasis on its safety and efficacy in treating pediatric keratoconus patients. This non-invasive treatment option is positioned to advance care standards in the ophthalmic industry.
About Glaukos (GKOS, Financial): Based in Aliso Viejo, California, Glaukos specializes in novel therapies for glaucoma, corneal disorders, and retinal diseases. Their proprietary technologies, such as Micro-Invasive Glaucoma Surgery (MIGS), continue to shape the future of ophthalmic treatment. For more information, visit their website.
